Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways
Barrett T., Slough R., Sushentsev N., Shaida N., Koo B. C., Caglic I., Kozlov V. V., Warren A. Y., Thankappannair V., Pinnock C., Shah N., Saeb-Parsy K., Gnanapragasam V. J., Sala E., Kastner C.
Clinical Radiology
Vol.74, Issue11, P. 894.e1-894.e9
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.1016/j.crad.2019.06.004
Аннотация:
AIM: To evaluate the effect of pre-biopsy magnetic resonance imaging (MRI) on cancer diagnostic times, and to report MRI-directed pathology outcomes. MATERIALS AND METHODS: In total, 1483 patients were referred with prostate cancer suspicion during a 30-month period. Upfront MRI was performed in 745 patients: 332 MRIs in the 15 months prior to dedicated scanning slots (group 1), and 413 in the 15 months post-introduction (group 2). A further 88 patients had initial MRI following clinical assessment. Biopsy via the transrectal (TR) or transperineal (TP) approach was performed, with MRI/ultrasound fusion for MRI targets. Clinically significant cancer (csPCa) was defined as Gleason ≥3+4. Negative MRIs were defined as Likert 1–2. Per-case clinical decisions were taken to biopsy or not. RESULTS: 44.4[%] of patients avoided biopsy. 484/833 (58.1[%]) MRIs were negative; 37.4[%] of these patients had biopsy with a negative predictive value (NPV) of 92.8[%] for Gleason ≥3+4 and 98.3[%] for ≥4+3. Overall
Ключевые слова:
gadobutrol; prostate specific antigen; scopolamine butyl bromide; adult; aged; Article; biopsy technique; bone scintiscanning; cancer diagnosis; cancer patient; clinical assessment; clinical outcome; computer assisted tomography; diagnostic test accuracy study; diffusion weighted imaging; dynamic contrast-enhanced magnetic resonance imaging; electron spin resonance; Gleason score; histopathology; human; major clinical study; male; middle aged; nuclear magnetic resonance imaging; predictive value; prevalence; priority journal; prostate biopsy; prostate cancer; radiological parameters; retrospective study; risk assessment; three dimensional imaging; transperineal biopsy; transrectal ultrasonography; tumor biopsy; cancer grading; clinical pathway; early cancer diagnosis; image guided biopsy; multiparametric magnetic resonance imaging; pathology; procedures; prospective study; prostate; prostate tumor; time factor; treatment outcome; Aged; Critical Pathways; Early Detection of Cancer; Huma
Язык текста: Английский
ISSN: 1365-229X
Barrett T.
Slough R.
Sushentsev N.
Shaida N.
Koo B. C.
Caglic I.
Kozlov V. V. Vasilij Vladimirovich 1974-
Warren A. Y.
Thankappannair V.
Pinnock C.
Shah N.
Saeb-Parsy K.
Gnanapragasam V. J.
Sala E.
Kastner C.
Барретт Т.
Слоугх Р.
Сушенцев Н.
Шаида Н.
Коо Б. C.
Cаглиc И.
Козлов В. В. Василий Владимирович 1974-
Wаррен А. Y.
Тханкаппаннаир В.
Пинноcк C.
Шах Н.
Саеб-Парсy К.
Гнанапрагасам В. Й.
Сала Е.
Кастнер C.
Three-year experience of a dedicated prostate mpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways
Текст визуальный непосредственный
Clinical Radiology
W.B. Saunders
Vol.74, Issue11 P. 894.e1-894.e9
2019
Статья
gadobutrol prostate specific antigen scopolamine butyl bromide adult aged Article biopsy technique bone scintiscanning cancer diagnosis cancer patient clinical assessment clinical outcome computer assisted tomography diagnostic test accuracy study diffusion weighted imaging dynamic contrast-enhanced magnetic resonance imaging electron spin resonance Gleason score histopathology human major clinical study male middle aged nuclear magnetic resonance imaging predictive value prevalence priority journal prostate biopsy prostate cancer radiological parameters retrospective study risk assessment three dimensional imaging transperineal biopsy transrectal ultrasonography tumor biopsy cancer grading clinical pathway early cancer diagnosis image guided biopsy multiparametric magnetic resonance imaging pathology procedures prospective study prostate prostate tumor time factor treatment outcome Aged Critical Pathways Early Detection of Cancer Huma
AIM: To evaluate the effect of pre-biopsy magnetic resonance imaging (MRI) on cancer diagnostic times, and to report MRI-directed pathology outcomes. MATERIALS AND METHODS: In total, 1483 patients were referred with prostate cancer suspicion during a 30-month period. Upfront MRI was performed in 745 patients: 332 MRIs in the 15 months prior to dedicated scanning slots (group 1), and 413 in the 15 months post-introduction (group 2). A further 88 patients had initial MRI following clinical assessment. Biopsy via the transrectal (TR) or transperineal (TP) approach was performed, with MRI/ultrasound fusion for MRI targets. Clinically significant cancer (csPCa) was defined as Gleason ≥3+4. Negative MRIs were defined as Likert 1–2. Per-case clinical decisions were taken to biopsy or not. RESULTS: 44.4[%] of patients avoided biopsy. 484/833 (58.1[%]) MRIs were negative; 37.4[%] of these patients had biopsy with a negative predictive value (NPV) of 92.8[%] for Gleason ≥3+4 and 98.3[%] for ≥4+3. Overall